Regen BioPharma, Inc.
RGBP
$0.055
$0.0011.85%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| SG&A Expenses | 35.02% | 35.58% | 18.23% | -68.58% | -10.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.95% | 15.81% | 16.10% | -65.23% | -24.57% |
| Operating Income | -46.19% | -26.76% | -28.30% | 73.53% | 39.57% |
| Income Before Tax | 18.49% | -31.15% | -122.73% | -121.39% | -316.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.49% | -31.15% | -122.73% | -121.39% | -316.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.49% | -31.15% | -122.73% | -121.39% | -316.67% |
| EBIT | -46.19% | -26.76% | -28.30% | 73.53% | 39.57% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 15.56% | 5.44% | 6.63% | -122.55% | -204.39% |
| Normalized Basic EPS | 27.38% | -5.43% | 6.73% | -108.29% | 36.68% |
| EPS Diluted | 15.56% | 5.44% | 6.63% | -122.55% | -204.39% |
| Normalized Diluted EPS | 27.38% | -5.43% | 6.73% | -108.29% | 36.68% |
| Average Basic Shares Outstanding | 11.89% | 24.61% | 137.92% | 7.01% | 36.64% |
| Average Diluted Shares Outstanding | 11.89% | 24.61% | 137.92% | 7.01% | 36.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |